HC Wainwright reaffirmed their buy rating on shares of Celcuity (NASDAQ:CELC – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $27.00 price objective on the stock.
Several other equities research analysts have also weighed in on the company. Stifel Nicolaus lifted their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Leerink Partners initiated coverage on shares of Celcuity in a research note on Monday, July 22nd. They set an “outperform” rating and a $29.00 price target on the stock. Lifesci Capital began coverage on shares of Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective for the company. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Celcuity in a report on Friday. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $29.17.
Get Our Latest Stock Report on CELC
Celcuity Stock Performance
Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the previous year, the business posted ($0.66) EPS. Analysts predict that Celcuity will post -2.54 EPS for the current year.
Institutional Investors Weigh In On Celcuity
Several large investors have recently added to or reduced their stakes in CELC. Geode Capital Management LLC increased its stake in Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after acquiring an additional 136,518 shares during the last quarter. Barclays PLC increased its position in shares of Celcuity by 567.6% in the third quarter. Barclays PLC now owns 53,605 shares of the company’s stock worth $800,000 after purchasing an additional 45,576 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Celcuity in the third quarter worth approximately $205,000. XTX Topco Ltd purchased a new stake in Celcuity in the third quarter valued at approximately $307,000. Finally, Wellington Management Group LLP bought a new stake in Celcuity during the third quarter valued at approximately $770,000. Institutional investors own 63.33% of the company’s stock.
About Celcuity
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Recommended Stories
- Five stocks we like better than Celcuity
- 3 Warren Buffett Stocks to Buy Now
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How to Invest in Insurance Companies: A GuideĀ
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Election Stocks: How Elections Affect the Stock Market
- Time to Load Up on Home Builders?
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.